Research programme: autoimmune disease therapy - Lexicon Pharmaceuticals

Drug Profile

Research programme: autoimmune disease therapy - Lexicon Pharmaceuticals

Alternative Names: LX 2311; LX 2932

Latest Information Update: 13 Feb 2014

Price : $50

At a glance

  • Originator Lexicon Genetics
  • Developer Lexicon Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Lyase inhibitors; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders

Most Recent Events

  • 13 Jan 2014 Discontinued - Preclinical for Autoimmune disorders in USA (PO)
  • 11 Dec 2007 Pharmacodynamics data from a preclinical study presented at the 49th Annual Meeting and Exposition of the American Society of Hematology (ASH-2007)
  • 12 Nov 2007 Lexicon Pharmaceuticals files an IND with the FDA in the US for LX 2931 in the treatment of rheumatoid arthritis and autoimmune disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top